Health

On 18 April 2026, President Trump signed the Executive Order ‘Accelerating medical treatments for serious mental illness’, which directs federal agencies to speed up research, regulatory review, and access pathways for psychedelic therapies. Brevia Health has examined the scope of the Executive Order, the potential timeline of these developments and how this could impact the UK.

Discover the impact of the MHRA and NICE’s new aligned pathway on medicine approval timelines in England.

The Government’s landmark 10 Year Health Plan for England, “Fit for the Future”, was published on 3 July 2025. The Plan aims to create a new model of care, building on the NHS’ founding principles and redesigning how the NHS delivers so that patients have real choice and control over their care.

NICE announced on 9 February 2026 the launch of its new National HealthTech Access Programme (NHAP). The NHAP is set to expand NICE’s technology appraisals programme to incorporate health technologies.

The Government has published the long-awaited National Cancer Plan for England setting out how the DHSC and the NHS, will improve cancer prevention, diagnosis, treatment and research across England.

Brevia Health has been awarded the Best Healthcare Public Affairs & Market Access Consultancy in 2025.

Prime Minister, Sir Keir Starmer MP, has said his Government is committed to reducing healthcare expenses for families, during a visit to a pharmacy in London on Monday 26 January, according to Pharmacy Business.

The Medicines and Healthcare products Regulatory Agency (MHRA) set out on 13 January 2026, the next phase of reforms aimed at strengthening the clinical trial landscape in the UK. These reforms come at a time of renewed momentum for clinical research.

NICE has announced that Professor Jonathan Benger CBE will be its next Chief Executive, from Friday 19 December 2025. Professor Benger replaces Dr Samantha Jones, who has held the post since 2021.

The UK Government announced on 1 December 2025 a landmark deal that is expected to benefit NHS patients by expanding access to vital medicines, strengthening the UK’s pharmaceutical supply chain, and attracting new investment into the country’s life sciences sector.